Detalhe da pesquisa
1.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32487038
2.
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
World J Urol
; 37(12): 2623-2629, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-30191396
3.
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Prostate
; 78(8): 623-630, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29520847
4.
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
BMC Cancer
; 17(1): 453, 2017 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-28662647
5.
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.
Adv Radiat Oncol
; 9(7): 101507, 2024 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-38799104
6.
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer.
Adv Radiat Oncol
; 5(2): 260-268, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32280826
7.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 6(5): 650-659, 2020 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32215577
8.
Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
Urol Oncol
; 36(6): 309.e7-309.e14, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29551548